2.5M shares for resale by selling holders — ImageneBio (NASDAQ: IMA)

Rhea-AI Filing Summary

ImageneBio, Inc. registers 2,508,337 shares of Common Stock for resale by the selling stockholders identified in the prospectus supplement. The resale prospectus supplement updates the Form S-1 registration (No. 333-290108) and incorporates specified portions of the company’s Form 10-Q filed May 7, 2026.

The Common Stock trades on the Nasdaq Capital Market under the symbol IMA; the last reported sales price on May 6, 2026 was $6.08 per share. The prospectus supplement states proceeds from resales will be received by the selling stockholders, not the issuer.

Key Figures

Registered shares: 2,508,337 shares Last reported sales price: $6.08 per share Registration number: No. 333-290108 +1 more

4 metrics

Registered shares 2,508,337 shares registered for resale in prospectus supplement

Last reported sales price $6.08 per share last reported on May 6, 2026

Registration number No. 333-290108 Form S-1 registration statement

Prospectus supplement date May 7, 2026 date of this prospectus supplement

Key Terms

prospectus supplement, selling stockholders, Form S-1

3 terms

prospectus supplement regulatory

"This prospectus supplement supplements the prospectus dated April 2, 2026"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

selling stockholders financial

"resale or other disposition from time to time by the selling stockholders identified in this prospectus"

Selling stockholders are existing owners of a company's shares who are offering some or all of their holdings for sale, often as part of a public offering or secondary transaction. For investors this matters because such sales increase the number of shares available to buy, can signal how confident current owners are about future prospects, and may put short-term pressure on the stock price similar to more tickets being released for a popular event.

Form S-1 regulatory

"registration statement on Form S-1 (No. 333-290108), as amended"

A Form S-1 is the registration filing a company submits to the U.S. Securities and Exchange Commission when it plans to offer stock to the public, most commonly for an initial public offering. Think of it as the company’s full disclosure packet or blueprint: it contains audited financials, business description, management background, risk factors and details of the offering, giving investors the information needed to judge the company’s financial health and potential risks before buying shares.

Offering Details

resale/secondary

Offering

Offering Type resale/secondary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 05:23 PM Learn about SEC filing dates

FAQ

What does ImageneBio's prospectus supplement (IMA) register?

The supplement registers 2,508,337 shares of common stock for resale by identified selling stockholders. The offering is a resale of existing shares under the Form S-1 registration statement No. 333-290108 and supplements the April 2, 2026 prospectus.

Will ImageneBio (IMA) receive proceeds from the resale of these shares?

No. The prospectus supplement states these are resales by selling stockholders and proceeds will be received by those selling holders, not by ImageneBio. The filing describes the offering as resale/secondary distribution.

On which exchange does ImageneBio (IMA) trade and what was the last reported price?

ImageneBio's common stock is listed on the Nasdaq Capital Market under the symbol IMA. The last reported sales price shown in the supplement on May 6, 2026 was $6.08 per share.

What filing does this prospectus supplement incorporate by reference?

The supplement incorporates certain information from ImageneBio’s Quarterly Report on Form 10-Q filed on May 7, 2026. It updates and supplements the prospectus dated April 2, 2026 that is part of the Form S-1 registration.

Does the prospectus supplement change the registration statement number for ImageneBio (IMA)?

No. The supplement references and supplements the existing registration statement on Form S-1 identified as No. 333-290108. It does not replace or assign a new registration number; it updates information within that registration.

Filed Pursuant to Rule 424(b)(3)

Registration No. 333-290108

PROSPECTUS SUPPLEMENT

(To Prospectus dated April 2, 2026)

ImageneBio, Inc.

2,508,337 Shares of Common Stock

This prospectus supplement supplements the prospectus dated April 2, 2026 (the “Prospectus”), which forms a part of our registration statement on Form S-1 (No. 333-290108), as amended. This prospectus supplement is being filed to update and supplement the information in the Prospectus with certain information contained in our Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 7, 2026 (the “Quarterly Report”). Accordingly, we have attached the Quarterly Report in relevant part to this prospectus supplement.

The Prospectus and this prospectus supplement relate to the proposed offer and resale or other disposition from time to time by the selling stockholders identified in this prospectus of 2,508,337 shares of common stock, par value $0.001 per share, (the “Common Stock”) of ImageneBio, Inc.

Our Common Stock is listed on the Nasdaq Capital Market under the ticker symbol “IMA.” On May 6, 2026, the last reported sales price of our Common Stock was $6.08 per share.

This prospectus supplement should be read in conjunction with the Prospectus, including any amendments or supplements to it, which is to be delivered with this prospectus supplement. This prospectus supplement is qualified by reference to the Prospectus, including any amendments or supplements thereto, except to the extent that the information provided by this prospectus supplement supersedes information contained in the Prospectus.

This prospectus supplement is not complete without, and may not be delivered or used except in conjunction with, the Prospectus, including any amendments or supplements to it.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled “Risk Factors” beginning on page 6 of the Prospectus, and under similar headings in any amendments or supplements to the Prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is May 7, 2026